HDR-CRISPR promotes targeted genome editing with reduced mutational burden in primary human cells [Amp-seq]
We have established a technology to endorse DSB resolution via HDR with the goal of facilitating clinical transition of HDR-based editing strategies and increase safety. We have used high throughput sequencing as deposited here to assess safety of our platform Overall design: We have performed Amplicon Sequencing to monitor gross genomic aberration between control samples and samples that have received our HDR-promoting tools